CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Investigational New Drug Application (“IND”) for its patent pending, abuse deterrent, sustained release, oral opioid formulation COL-003 is now active following its acceptance by the U.S. Food and Drug Administration (FDA). The Company submitted the IND in June 2007.
